timothy sykes logo

Stock News

Vision Marine Technologies Soars as Wall Street Awaits Economic Indicators

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 12/21/2025, 8:13 am ET 12/21/2025, 8:13 am ET | 5 min 5 min read
Vision Marine Technologies Soars as Wall Street Awaits Economic Indicators Thumbnail

NovaBay Pharmaceuticals Inc.’s stocks have been trading up by 84.41 percent, driven by promising pipeline results that boosted investor confidence.

Healthcare industry expert:

Analyst sentiment – neutral

NovaBay Pharmaceuticals, Inc. (NBY) currently holds a precarious market position characterized by strikingly high EBIT and EBITDA margins of 110.4% and 117.4%, respectively. However, these are overshadowed by a substantial pre-tax profit margin deficit of -127.9%, indicating severe cost management challenges. The company’s revenue stream reflects a dire contraction, with a three-year growth rate at -36.19%. With a price-to-book ratio soaring at 602.22 and an alarming price-to-sales ratio of 235.99, the market valuation appears unsustainable. Despite poor earnings metrics with a Price/Earnings ratio of 0.18, these figures suggest that investors perceive potential value not immediately apparent in the financials, albeit with considerable risk.

From a technical standpoint, NBY’s recent weekly price movements suggest a bullish reversal, with the stock closing at $5.44—well above previous trading levels. The five-minute candlestick analysis indicates a pattern of higher lows, confirming an emerging upward trend. The spike in price on December 19, characterized by significant volume, underscores a shift in market sentiment. A strategic entry point for traders lies around the $5.00 support level, with a prudent stop-loss near the $4.90 mark to mitigate downward risks. The next resistance level stands around $5.70, and traders could target this as a potential profit-taking point as long as volume patterns maintain the current upward momentum.

In terms of catalysts, recent macroeconomic news has demonstrated little direct impact on NBY’s stock. Nevertheless, the broader sectoral volatility provides an advantageous backdrop for companies like NovaBay that are less encumbered by regulatory upheavals. Despite potential parallels to underperformers like Galectin Therapeutics, NBY remains distinct with unique product lines. Within the Healthcare and Biotechnology & Life Sciences arenas, NovaBay’s current market positioning implies potential for modest recovery, albeit saddled with substantial execution risk. Positioning for the near term remains cautious, yet positive gains could surface provided that operational efficiency improves. Resistance remains strong at $6.00, with short-term support at $5.00.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Sunday, December 21, 2025 NovaBay Pharmaceuticals Inc. stock [NYSE American: NBY] is trending up by 84.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent trading sessions, NovaBay Pharmaceuticals Inc. (NBY) witnessed a significant fluctuation in its share prices. A few months back, between December 15 and December 19, its stock opened at $2.71 and closed at $5.44, reflecting a volatile trading period. This kind of movement often attracts both traders and investors, as it suggests opportunities for capturing short-term gains. Analyzing the price swings, it is evident that NBY’s shares experienced a pivotal moment as they climbed sharply in mid-December, potentially driven by market speculation or corporate news.

Focusing on NovaBay’s earnings report and financial metrics, the company’s data paints a complex picture. Revenue stood at roughly $9.78M, indicating a decline in sales performance over both three- and five-year periods. With a profit margin showing signs of struggle, alongside negative earnings per share (EPS), the fundamental figures highlight existing challenges. Furthermore, key ratios expose a concerning leverage scenario, with high debt to equity, which could be critical in a rising rate environment, potentially affecting liquidity and cash flow.

More Breaking News

The balance sheet reveals a cash position of $1.11M at the quarter’s end, down sharply from previous periods. This presents a liquidity concern and may impact operational strategies moving forward. The overall financial framework suggests NovaBay must address these core issues to achieve stability and regain positive momentum. Strategic decisions regarding cost control or new revenue streams will be crucial in the coming quarters.

Conclusion

NovaBay Pharmaceuticals faces a decisive moment as it navigates a mix of internal financial difficulties and an external environment marked by significant market moves. While Vision Marine Technologies exemplifies the potential of trader enthusiasm driving stock value, Galectin Therapeutics highlights the pitfalls of regulatory setbacks. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This wisdom should be at the forefront of NBY’s near-term focus, steering financial strategies toward sustainable operating models while cautiously observing potential market shifts. Aligning with trader expectations can harness possible upsides in this dynamic landscape. In doing so, NovaBay might transform volatility into a strategic advantage amidst the ever-shifting gears of the financial market.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”